Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) has coverage initiated with a Neutral rating

Analyst Ratings For Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)

Story continues below

Today, Goldman Sachs Group initiated coverage on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) with a Neutral.

There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) is Buy with a consensus target price of $37.50 per share, a potential 53.12% upside.

Some recent analyst ratings include

  • 7/26/2018-Goldman Sachs Group initiated coverage with a Neutral rating.
  • 7/17/2018-Wells Fargo & Co initiated coverage with a Outperform rating.
  • 7/17/2018-William Blair initiated coverage with a Outperform rating.
  • 7/17/2018-Jefferies Financial Group initiated coverage with a Buy rating.


    About Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)
    Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours. The company was incorporated in 2018 and is headquartered in London, the United Kingdom.

    Recent Trading Activity for Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)
    Shares of Autolus Therapeutics Ltd – ADR closed the previous trading session at 24,49 +0,14 0,57 % with 23.66 shares trading hands.

    An ad to help with our costs